Dr. Leclerc, you've talked already about funding. During our study on antimicrobial resistance, we heard about a push-pull mechanism as an incentive for companies to produce drugs here in Canada when the drugs are perhaps critical but are used only in small quantities. Do you have any comments in that regard?
